Castle Reconciled Depreciation vs Ebitda Analysis

CSTL Stock

USD 30.28 0.16 0.53%

Castle Biosciences financial indicator trend analysis is way more than just evaluating Castle Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Castle Biosciences is a good investment. Please check the relationship between Castle Biosciences Reconciled Depreciation and its Ebitda accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.

Reconciled Depreciation vs Ebitda

Reconciled Depreciation vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Castle Biosciences Reconciled Depreciation account and Ebitda. At this time, the significance of the direction appears to have pay attention.

The correlation between Castle Biosciences' Reconciled Depreciation and Ebitda is -0.91. Overlapping area represents the amount of variation of Reconciled Depreciation that can explain the historical movement of Ebitda in the same time period over historical financial statements of Castle Biosciences, assuming nothing else is changed. The correlation between historical values of Castle Biosciences' Reconciled Depreciation and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Reconciled Depreciation of Castle Biosciences are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Reconciled Depreciation i.e., Castle Biosciences' Reconciled Depreciation and Ebitda go up and down completely randomly.

Correlation Coefficient

-0.91

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Reconciled Depreciation

Ebitda

Most indicators from Castle Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Castle Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.Tax Provision is expected to rise to about 125 K this year, although the value of Selling General Administrative will most likely fall to about 50.2 M.

	2021	2022	2023	2024 (projected)
Interest Expense	1K	17K	11K	10.5K
Depreciation And Amortization	3.4M	10.5M	12.3M	12.9M

Interest Expense Depreciation And Amortization

Castle Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets
Total Assets		-0.77	0.83	0.91	1.0	0.41	0.98	0.78	0.81	-0.82	-0.72	0.64	0.83	0.8	-0.36	0.71	0.42	0.97	0.82	0.95	0.96	0.42	-0.48	0.91	0.72	0.97
Short Long Term Debt Total	-0.77		-0.52	-0.53	-0.79	-0.56	-0.78	-0.5	-0.34	0.8	0.41	-0.34	-0.8	-0.53	0.17	-0.64	0.02	-0.81	-0.35	-0.64	-0.75	0.02	0.5	-0.54	-0.4	-0.85
Other Current Liab	0.83	-0.52		0.91	0.82	0.12	0.76	0.99	0.78	-0.43	-0.98	0.94	0.5	0.97	-0.31	0.59	0.6	0.72	0.89	0.9	0.88	0.6	-0.37	0.86	0.97	0.72
Total Current Liabilities	0.91	-0.53	0.91		0.9	0.16	0.86	0.88	0.79	-0.53	-0.88	0.8	0.55	0.89	-0.4	0.57	0.51	0.79	0.97	0.9	0.93	0.51	-0.41	0.87	0.85	0.78
Total Stockholder Equity	1.0	-0.79	0.82	0.9		0.41	0.99	0.76	0.8	-0.84	-0.7	0.63	0.85	0.78	-0.36	0.71	0.41	0.97	0.8	0.94	0.95	0.41	-0.5	0.9	0.71	0.97
Other Liab	0.41	-0.56	0.12	0.16	0.41		0.39	0.08	0.21	-0.58	0.02	-0.09	0.56	0.21	0.16	0.53	-0.02	0.44	0.1	0.28	0.4	-0.02	0.37	0.25	-0.05	0.54
Net Tangible Assets	0.98	-0.78	0.76	0.86	0.99	0.39		0.69	0.8	-0.89	-0.63	0.57	0.9	0.69	-0.28	0.67	0.38	0.99	0.76	0.93	0.89	0.38	-0.56	0.9	0.66	0.98
Property Plant And Equipment Net	0.78	-0.5	0.99	0.88	0.76	0.08	0.69		0.71	-0.35	-0.99	0.96	0.42	0.97	-0.28	0.56	0.57	0.65	0.87	0.85	0.85	0.57	-0.34	0.79	0.97	0.65
Current Deferred Revenue	0.81	-0.34	0.78	0.79	0.8	0.21	0.8	0.71		-0.63	-0.68	0.67	0.68	0.7	-0.22	0.67	0.8	0.78	0.83	0.88	0.74	0.8	-0.26	0.89	0.73	0.76
Net Debt	-0.82	0.8	-0.43	-0.53	-0.84	-0.58	-0.89	-0.35	-0.63		0.25	-0.22	-0.99	-0.36	0.08	-0.64	-0.19	-0.93	-0.42	-0.74	-0.66	-0.19	0.47	-0.72	-0.32	-0.93
Retained Earnings	-0.72	0.41	-0.98	-0.88	-0.7	0.02	-0.63	-0.99	-0.68	0.25		-0.97	-0.31	-0.96	0.3	-0.51	-0.59	-0.57	-0.88	-0.8	-0.82	-0.59	0.33	-0.74	-0.98	-0.57
Accounts Payable	0.64	-0.34	0.94	0.8	0.63	-0.09	0.57	0.96	0.67	-0.22	-0.97		0.3	0.88	-0.11	0.46	0.63	0.52	0.83	0.77	0.71	0.63	-0.35	0.73	0.99	0.51
Cash	0.83	-0.8	0.5	0.55	0.85	0.56	0.9	0.42	0.68	-0.99	-0.31	0.3		0.42	-0.06	0.65	0.25	0.94	0.44	0.78	0.67	0.25	-0.48	0.76	0.4	0.94
Non Current Assets Total	0.8	-0.53	0.97	0.89	0.78	0.21	0.69	0.97	0.7	-0.36	-0.96	0.88	0.42		-0.41	0.58	0.52	0.65	0.85	0.84	0.9	0.52	-0.24	0.78	0.9	0.67
Non Currrent Assets Other	-0.36	0.17	-0.31	-0.4	-0.36	0.16	-0.28	-0.28	-0.22	0.08	0.3	-0.11	-0.06	-0.41		-0.02	0.04	-0.26	-0.29	-0.28	-0.41	0.04	0.3	-0.27	-0.16	-0.22
Other Assets	0.71	-0.64	0.59	0.57	0.71	0.53	0.67	0.56	0.67	-0.64	-0.51	0.46	0.65	0.58	-0.02		0.66	0.7	0.57	0.6	0.75	0.66	-0.11	0.5	0.52	0.75
Long Term Debt	0.42	0.02	0.6	0.51	0.41	-0.02	0.38	0.57	0.8	-0.19	-0.59	0.63	0.25	0.52	0.04	0.66		0.36	0.66	0.5	0.45	1.0	0.02	0.49	0.65	0.36
Cash And Short Term Investments	0.97	-0.81	0.72	0.79	0.97	0.44	0.99	0.65	0.78	-0.93	-0.57	0.52	0.94	0.65	-0.26	0.7	0.36		0.69	0.92	0.86	0.36	-0.56	0.88	0.61	0.99
Net Receivables	0.82	-0.35	0.89	0.97	0.8	0.1	0.76	0.87	0.83	-0.42	-0.88	0.83	0.44	0.85	-0.29	0.57	0.66	0.69		0.85	0.86	0.66	-0.28	0.83	0.86	0.68
Common Stock Total Equity	0.95	-0.64	0.9	0.9	0.94	0.28	0.93	0.85	0.88	-0.74	-0.8	0.77	0.78	0.84	-0.28	0.6	0.5	0.92	0.85		0.88	0.5	-0.49	0.99	0.84	0.9
Common Stock Shares Outstanding	0.96	-0.75	0.88	0.93	0.95	0.4	0.89	0.85	0.74	-0.66	-0.82	0.71	0.67	0.9	-0.41	0.75	0.45	0.86	0.86	0.88		0.45	-0.36	0.81	0.77	0.88
Long Term Debt Total	0.42	0.02	0.6	0.51	0.41	-0.02	0.38	0.57	0.8	-0.19	-0.59	0.63	0.25	0.52	0.04	0.66	1.0	0.36	0.66	0.5	0.45		0.02	0.49	0.65	0.36
Non Current Liabilities Total	-0.48	0.5	-0.37	-0.41	-0.5	0.37	-0.56	-0.34	-0.26	0.47	0.33	-0.35	-0.48	-0.24	0.3	-0.11	0.02	-0.56	-0.28	-0.49	-0.36	0.02		-0.46	-0.41	-0.47
Capital Surpluse	0.91	-0.54	0.86	0.87	0.9	0.25	0.9	0.79	0.89	-0.72	-0.74	0.73	0.76	0.78	-0.27	0.5	0.49	0.88	0.83	0.99	0.81	0.49	-0.46		0.79	0.86
Inventory	0.72	-0.4	0.97	0.85	0.71	-0.05	0.66	0.97	0.73	-0.32	-0.98	0.99	0.4	0.9	-0.16	0.52	0.65	0.61	0.86	0.84	0.77	0.65	-0.41	0.79		0.6
Other Current Assets	0.97	-0.85	0.72	0.78	0.97	0.54	0.98	0.65	0.76	-0.93	-0.57	0.51	0.94	0.67	-0.22	0.75	0.36	0.99	0.68	0.9	0.88	0.36	-0.47	0.86	0.6

Click cells to compare fundamentals

Castle Biosciences Account Relationship Matchups

Castle Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	119.7M	439.3M	462.6M	447.3M	453.3M	307.1M
Short Long Term Debt Total	24.5M	25.1M	8.1M	13.3M	15.3M	14.0M
Other Current Liab	7.6M	12.1M	19.3M	27.8M	35.1M	36.9M
Total Current Liabilities	15.3M	20.9M	24.9M	36.1M	47.7M	24.6M
Total Stockholder Equity	85.1M	415.7M	411.7M	399.2M	391.3M	263.8M
Other Liab	55K	2.8M	19.0M	428K	492.2K	467.6K
Net Tangible Assets	85.1M	415.7M	322.8M	272.8M	313.7M	181.4M
Property Plant And Equipment Net	2.1M	7.1M	16.9M	26.5M	37.7M	39.6M
Net Debt	(73.7M)	(409.9M)	(321.6M)	(109.6M)	(83.5M)	(87.7M)
Retained Earnings	(52.2M)	(62.5M)	(93.8M)	(160.9M)	(218.4M)	(207.5M)
Accounts Payable	1.9M	2.1M	2.5M	4.7M	10.3M	10.8M
Cash	98.8M	409.9M	329.6M	122.9M	98.8M	167.5M
Non Current Assets Total	3.1M	9.7M	108.8M	155.0M	157.7M	165.6M
Non Currrent Assets Other	135K	1.5M	3.0M	(25.6M)	2.6M	2.8M
Other Assets	1.0M	2.6M	3.0M	2.2M	2.5M	2.4M
Cash And Short Term Investments	98.8M	409.9M	329.6M	258.6M	243.1M	211.5M
Net Receivables	14.6M	12.8M	17.3M	23.5M	38.3M	19.4M
Common Stock Shares Outstanding	8.7M	18.9M	25.1M	26.1M	26.8M	19.8M
Liabilities And Stockholders Equity	119.7M	439.3M	462.6M	447.3M	453.3M	307.1M
Non Current Liabilities Total	19.3M	2.8M	25.9M	12.1M	14.4M	13.6M
Inventory	1.2M	2.2M	2.0M	4.0M	7.9M	8.3M
Other Current Assets	2.0M	9.5M	9.6M	6.2M	6.3M	5.5M
Other Stockholder Equity	137.3M	478.2M	505.5M	560.4M	609.5M	360.5M
Total Liab	34.6M	23.6M	50.8M	48.2M	62.1M	43.4M
Net Invested Capital	110.2M	415.7M	411.7M	399.2M	391.3M	261.5M
Property Plant And Equipment Gross	2.1M	7.1M	16.9M	26.5M	45.9M	48.1M
Total Current Assets	116.7M	429.6M	353.7M	292.3M	295.6M	237.7M
Accumulated Other Comprehensive Income	(909.4K)	(119.7M)	0.0	(381K)	136K	142.8K
Net Working Capital	101.4M	408.7M	328.9M	256.2M	248.0M	213.1M
Common Stock	1.9K	17K	25K	27K	31.1K	19.6K
Property Plant Equipment	2.1M	7.1M	16.9M	26.5M	30.5M	32.0M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Castle Biosciences is a strong investment it is important to analyze Castle Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Castle Biosciences' future performance. For an informed investment choice regarding Castle Stock, refer to the following important reports:

How To Invest In Castle

Details

Is Castle Stock a good investment?

Details

What is Castle Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.

You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.93)

Earnings Share

0.21

Revenue Per Share

11.34

Quarterly Revenue Growth

0.395

Return On Assets

(0)

The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Castle Reconciled Depreciation vs Ebitda Analysis

Reconciled Depreciation vs Ebitda

Reconciled Depreciation vs Ebitda Correlation Analysis

Correlation Coefficient

Reconciled Depreciation

Ebitda

Castle Biosciences fundamental ratios Correlations

Castle Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Castle Biosciences fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Long Term Debt Total	+ 1.0	Long Term Debt
Property Plant And Equipment Net	+ 0.99	Other Current Liab
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Net Tangible Assets
Inventory	+ 0.99	Accounts Payable

Cash	- 0.99	Net Debt
Retained Earnings	- 0.99	Property Plant And Equipment Net
Inventory	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Other Current Liab
Accounts Payable	- 0.97	Retained Earnings
Non Current Assets Total	- 0.96	Retained Earnings